August 3, 2005 Biotech added slightly to its recent gains, though it never strayed very far from the flat line. At the close, the Centient Biotech 200 was at its high point for the day, up more than 16 points to close at 3816.12, a rise of .43%. Protein Design Labs climbed sharply higher after announcing a partnership with Biogen Idec to develop three Phase II antibodies, MannKind received a $175 million cash infusion (half from its chairman), Altana Chemie bought a specialty chemical manufacturer, which will result in Altana Pharma becoming a separate company, and GPC Biotech was 18% higher in advance of its earnings announcement tomorrow. More details...
